India Cuts Cancer Drug Prices by Up to 70% as New NPPA Caps Take Effect

Cancer medicines in India are about to get much cheaper. The country’s drug price regulator has capped the trade margin on 137 anti-cancer drugs at 30 percent of the maximum retail price, and the revised prices took effect on 9 November 2026. The government expects prices to fall by up to 70 percent, saving patients around ₹2,500 crore a year.

For families paying for cancer treatment, the change matters more than the percentages suggest. Cancer drugs are among the most expensive medicines in the world, and in India much of the cost falls directly on patients. A price cut of this size, applied across more than a hundred drugs at once, is the largest single intervention in cancer drug pricing the country has attempted.

What exactly changed

The National Pharmaceutical Pricing Authority, or NPPA, used Paragraph 19 of the Drugs (Prices Control) Order of 2013 to cap trade margins at 30 percent of the maximum retail price — the MRP — on 137 non-scheduled anti-cancer drugs. The notification was issued on 17 October 2026, and the revised prices came into effect on 9 November.

The cap works on the margin, not directly on the price. A trade margin is the gap between what a company sells a drug for and what the patient pays at the pharmacy. Where that gap was wider than 30 percent of the MRP, it must now come down to 30 percent — and the MRP falls with it. Where the margin was already within 30 percent, the price does not change. That distinction matters, because it means not every one of the 137 drugs gets cheaper, and the drugs that do get cheaper do not all fall by the same amount.

The drugs covered include immunotherapies used against more than 20 types of cancer, along with denosumab, pegfilgrastim and bevacizumab. Widely used brands on the list include pembrolizumab, durvalumab and osimertinib — drugs that, until now, have been among the most expensive in Indian oncology.

What patients should save

The government’s headline figure is a fall of up to 70 percent in maximum retail prices, with annual savings of ₹2,500 crore for patients. That is the official figure from the Press Information Bureau. One news digest put the annual relief higher, at ₹3,500 crore, but the official government figure is ₹2,500 crore, and that is the number this article uses.

Some individual brands will fall further than the headline. One example reported in the press is Anarzole, whose price fell from ₹695.76 to ₹73 — a cut of about 90 percent. That is a single brand’s figure, not the average, and it should not be read as the typical saving. The headline “up to 70 percent” is the right way to describe the change across the list.

The rollout is already moving. By 4 November, 70 companies had filed revised prices for 1,136 stock-keeping units covering 120 drugs, and the NPPA had published revised maximum retail prices for 543 brands. One report cites a list of 1,085 medicines — a different count from a different source, reflecting different ways of counting brands, strengths and pack sizes. The underlying fact is the same: most of the list has already been repriced.

The catch: old stock keeps the old price

The cut does not apply instantly to every box on a pharmacy shelf. Stock manufactured and packed before the revised prices took effect continues to sell at the old price until it is cleared. Only new batches carry the reduced prices. A patient buying this week may still pay the old price, and should check the manufacturing and price details on the pack.

The same applies to brands that were already inside the 30 percent margin. Their prices do not change, because there is nothing to cap. Patients who find a particular brand unchanged should not assume the order has failed — the cap only bites where the margin was above the limit.

Patients can check the revised price of a specific drug on the NPPA website, nppa.gov.in, or on the regulator’s ‘Pharma Sahi Daam’ app, which lists current prices by brand and strength. Checking before buying is the practical step the regulator itself recommends.

Why this matters now

Cancer drug prices have been a running argument in India for years. The drugs are often imported or made under licence, priced for global markets, and sold into a system where most patients pay out of pocket. Previous price controls covered a narrower set of essential medicines; this order reaches into high-cost oncology drugs that were outside the scheduled list, using the regulator’s emergency powers under Paragraph 19.

Whether the savings reach patients in full will depend on the next few weeks: how fast old stock clears, whether pharmacies pass on the revised prices, and whether companies challenge the cap. The regulator has published the revised prices; the test now is whether the price on the shelf matches the price on the list.

Frequently asked questions

Which drugs got cheaper? 137 non-scheduled anti-cancer drugs, including immunotherapies for more than 20 cancer types, denosumab, pegfilgrastim and bevacizumab. Widely used brands include pembrolizumab, durvalumab and osimertinib.

How much cheaper? The government expects maximum retail prices to fall by up to 70 percent, with annual savings of ₹2,500 crore. Individual brands may fall more — one reported example fell about 90 percent — but that is not the average.

When did the new prices take effect? 9 November 2026. The NPPA notification was issued on 17 October 2026.

Why is my medicine still at the old price? Old stock keeps the old price until it clears, and brands already within the 30 percent margin do not change. Check the revised price on nppa.gov.in or the ‘Pharma Sahi Daam’ app.

How do I check the revised price of my drug? On the NPPA website (nppa.gov.in) or the ‘Pharma Sahi Daam’ app, by brand name and strength.

Key takeaways

• NPPA capped trade margins at 30% of MRP on 137 anti-cancer drugs; revised prices effective 9 November 2026.
• Government expects prices to fall by up to 70%, saving patients ₹2,500 crore a year.
• 70 companies filed revised prices for 1,136 SKUs of 120 drugs by 4 November; NPPA published revised MRPs for 543 brands.
• Old stock keeps old prices; brands already within the 30% margin do not change.
• Check revised prices on nppa.gov.in or the ‘Pharma Sahi Daam’ app before buying.